Effect of vitaminC and E on MCI (mild cognitive impairment )among elderly people in Esfahan , iran

Effect of dietary supplementation of the elderly suffering from mild cognitive impairment (MCI) with antioxidant vitamins C and E in Esfahan, Iran.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104186217N1

Enrollment

222

Registered

2011-05-15

Start date

2011-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment (MCI). Mild cognitive disorder

Interventions

Intervention 1: Intervention group will receive daily antioxidants as follows: 400 mg vitamin C or L-ascorbic acid and 300 IU or mg vitamin E (Alfa- Tocopheryle Acetate), one time daily for one year

Treatment - Drugs

Placebo

Intervention group will receive daily antioxidants as follows: 400 mg vitamin C or L-ascorbic acid and 300 IU or mg vitamin E (Alfa- Tocopheryle Acetate), one time daily for one year.

Control group will take one time daily placebo manufactured exactly similar to the color, shape and size of Vitamin C and E tablets.

Eligibility

Sex/Gender

All

Age

60 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: a. Aged between 60-75 years old in both sexes. b. Educational level of fifth grade and upper. Exclusion Criteria: a. Dementia, Depression, Epilepsy, Mental retardation, History of temporary loss of consciousness more than 2 hours due to head trauma, Memory problems that interfered with daily functioning , History of brain surgery and any significant neurological disease . b. History taking in medicine such as: neuroleptic drugs, benzodiazepine, anti-Depression, anti-epilepsy and opioids 7 days before interview by MMSE. c. Severe CVD (cardiovascular disease), anemia , liver and kidney disorders and mal-absorption. d. Alcohol and opium addiction, smokers .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive Performance. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: The Informant Questionnaire on cognitive decline in the elderly(IQCODE) Questionaires.;Cognitive Performance. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: The mini–mental state examination(MMSE).	—

Secondary

Measure	Time frame
Measurment of Malondialdehyde assay for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurment of Serum total antioxidant capacity for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurments of 8-hydroxy-2'-deoxyguanosine for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurment of Glutathion for oxidative stress of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.	—

Measure

Time frame

Measurment of Malondialdehyde assay for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurment of Serum total antioxidant capacity for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurments of 8-hydroxy-2'-deoxyguanosine for oxidative stress status of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.;Measurment of Glutathion for oxidative stress of subjects. Timepoint: Before intervention, after intervention and 6 months after intervention. Method of measurement: laboratory Methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirmansour Alavi Naeini

Tehran University of Medical Sciences

amalavi@tums.ac.ir+98 21 8895 1395

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026